PRAX Praxis Precision Medicines Inc
Price (delayed)
$59.5
Market cap
$1.06B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.17
Enterprise value
$913.35M
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights
Highlights
PRAX's equity has soared by 82% from the previous quarter
PRAX's EPS has surged by 80% year-on-year and by 38% since the previous quarter
The revenue has increased by 21% year-on-year but it has declined by 19% since the previous quarter
The gross profit rose by 21% year-on-year but it has declined by 19% since the previous quarter
Key stats
What are the main financial stats of PRAX
Market
Valuations
Earnings
Shares outstanding
17.76M
Market cap
$1.06B
Enterprise value
$913.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
632.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
515.72
Revenue
$1.77M
EBIT
-$123.74M
EBITDA
-$122.42M
Free cash flow
-$95.26M
Per share
Balance sheet
Liquidity
EPS
-$9.17
Free cash flow per share
-$5.06
Book value per share
$24.5
Revenue per share
$0.09
TBVPS
$23.43
Total assets
$441.06M
Total liabilities
$21.96M
Debt
$1.95M
Equity
$419.1M
Working capital
$336.1M
Debt to equity
0
Current ratio
17.3
Quick ratio
17.06
Net debt/EBITDA
1.17
Margins
Efficiency
Dividend
EBITDA margin
-6,912.3%
Gross margin
100%
Net margin
-6,987%
Operating margin
-7,492.7%
Return on assets
-55.9%
Return on equity
-61.5%
Return on invested capital
-143.8%
Return on capital employed
-29.4%
Return on sales
-6,987%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRAX stock price
How has the Praxis Precision Medicines stock price performed over time
Intraday
3.08%
1 week
2.69%
1 month
12.58%
1 year
179.34%
YTD
167.06%
QTD
43.86%
Financial performance
How have Praxis Precision Medicines's revenue and profit performed over time
Revenue
$1.77M
Gross profit
$1.77M
Operating income
-$132.7M
Net income
-$123.74M
Gross margin
100%
Net margin
-6,987%
The net margin has increased by 35% year-on-year but it has declined by 22% since the previous quarter
PRAX's operating margin is up by 31% year-on-year but it is down by 26% since the previous quarter
The revenue has increased by 21% year-on-year but it has declined by 19% since the previous quarter
The net income has grown by 21% YoY
Growth
What is Praxis Precision Medicines's growth rate over time
Valuation
What is Praxis Precision Medicines stock price valuation
P/E
N/A
P/B
2.43
P/S
632.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
515.72
PRAX's EPS has surged by 80% year-on-year and by 38% since the previous quarter
PRAX's equity has soared by 82% from the previous quarter
PRAX's P/B is 9% below its last 4 quarters average of 2.6
The price to sales (P/S) is 144% more than the last 4 quarters average of 251.6
The revenue has increased by 21% year-on-year but it has declined by 19% since the previous quarter
Efficiency
How efficient is Praxis Precision Medicines business performance
The company's return on invested capital has surged by 88% YoY and by 84% QoQ
Praxis Precision Medicines's ROE has soared by 66% YoY and by 40% from the previous quarter
Praxis Precision Medicines's ROA has soared by 57% YoY and by 36% from the previous quarter
PRAX's return on sales is up by 35% year-on-year but it is down by 22% since the previous quarter
Dividends
What is PRAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRAX.
Financial health
How did Praxis Precision Medicines financials performed over time
The total assets has soared by 76% QoQ
The quick ratio has soared by 55% since the previous quarter
The debt is 100% smaller than the equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
PRAX's equity has soared by 82% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.